Sensus Healthcare Inc (NASDAQ:SRTS) – Equities researchers at B. Riley issued their Q3 2018 earnings estimates for shares of Sensus Healthcare in a research note issued to investors on Tuesday, September 25th, according to Zacks Investment Research. B. Riley analyst A. D’silva anticipates that the company will post earnings per share of ($0.12) for the quarter. B. Riley currently has a “Buy” rating and a $12.50 target price on the stock. B. Riley also issued estimates for Sensus Healthcare’s Q4 2018 earnings at ($0.02) EPS, FY2018 earnings at ($0.25) EPS, Q1 2019 earnings at ($0.06) EPS, Q2 2019 earnings at $0.04 EPS, Q3 2019 earnings at ($0.04) EPS, Q4 2019 earnings at $0.07 EPS, FY2019 earnings at $0.02 EPS and FY2020 earnings at $0.24 EPS.
Several other equities analysts have also recently commented on the company. HC Wainwright initiated coverage on Sensus Healthcare in a report on Monday, August 27th. They issued a “buy” rating and a $14.00 price target for the company. initiated coverage on Sensus Healthcare in a report on Friday, July 6th. They issued a “buy” rating and a $12.25 price target for the company. Roth Capital initiated coverage on Sensus Healthcare in a report on Wednesday, August 1st. They issued a “buy” rating and a $12.50 price target for the company. Finally, Maxim Group upped their price target on Sensus Healthcare from $9.00 to $10.00 and gave the company a “buy” rating in a report on Wednesday, September 19th. Six investment analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average target price of $12.25.
Sensus Healthcare stock traded up $0.10 during trading hours on Friday, hitting $7.16. The stock had a trading volume of 43,753 shares, compared to its average volume of 30,207. The company has a quick ratio of 3.49, a current ratio of 3.80 and a debt-to-equity ratio of 0.39. The stock has a market cap of $134.80 million, a price-to-earnings ratio of -25.57 and a beta of -1.29. Sensus Healthcare has a fifty-two week low of $4.91 and a fifty-two week high of $8.88.
Sensus Healthcare (NASDAQ:SRTS) last announced its earnings results on Thursday, August 2nd. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.01). The business had revenue of $6.06 million for the quarter, compared to the consensus estimate of $6.36 million. Sensus Healthcare had a negative net margin of 13.07% and a negative return on equity of 26.74%.
Several institutional investors and hedge funds have recently modified their holdings of SRTS. Commonwealth Equity Services LLC acquired a new position in shares of Sensus Healthcare in the 1st quarter worth approximately $140,000. Paradigm Capital Management Inc. NY acquired a new position in shares of Sensus Healthcare in the 2nd quarter worth approximately $152,000. BlackRock Inc. acquired a new position in shares of Sensus Healthcare in the 2nd quarter worth approximately $164,000. Renaissance Technologies LLC raised its holdings in shares of Sensus Healthcare by 141.1% in the 2nd quarter. Renaissance Technologies LLC now owns 27,488 shares of the company’s stock worth $200,000 after buying an additional 16,088 shares in the last quarter. Finally, Perkins Capital Management Inc. acquired a new position in shares of Sensus Healthcare in the 2nd quarter worth approximately $1,792,000. 7.25% of the stock is owned by institutional investors and hedge funds.
In other news, insider Joseph C. Sardano sold 6,170 shares of the stock in a transaction that occurred on Thursday, August 9th. The stock was sold at an average price of $7.50, for a total value of $46,275.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last three months, insiders sold 12,854 shares of company stock valued at $96,567. 41.10% of the stock is currently owned by insiders.
Sensus Healthcare Company Profile
Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Further Reading: What is the balance sheet?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.